看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 2.8x - 3.1x | 2.9x |
| Historical Pb Multiple | 0.8x - 64.2x | 3.3x |
| Fair Value | kr1,274 - kr1,408 | kr1,341 |
| Upside | 32.4% - 46.3% | 39.4% |
| Benchmarks | - | Full Ticker |
| Zealand Pharma A/S | - | CPSE:ZEAL |
| Bavarian Nordic A/S | - | CPSE:BAVA |
| Initiator Pharma A/S | - | OM:INIT |
| BioPorto A/S | - | CPSE:BIOPOR |
| Curasight A/S | - | NGM:CURAS |
| Strategic Partners A/S | - | CPSE:STRAP |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| ZEAL | BAVA | INIT | BIOPOR | CURAS | STRAP | |||
| CPSE:ZEAL | CPSE:BAVA | OM:INIT | CPSE:BIOPOR | NGM:CURAS | CPSE:STRAP | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 1038.3% | 101.1% | 12.8% | -68.7% | -33.9% | 98.9% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -793.0% | -1.2% | NA | -226.3% | NA | -6389.3% | ||
| Prior Fiscal Year | -205.3% | 20.9% | NA | -181.9% | NA | NA | ||
| Latest Fiscal Year | -1720.9% | 17.3% | NA | -188.3% | NA | NA | ||
| Latest Twelve Months | 73.3% | 22.0% | NA | -235.4% | NA | NA | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -57.8% | 2.8% | -105.2% | -111.8% | -66.9% | -80.1% | ||
| Prior Fiscal Year | -58.4% | 16.9% | -101.2% | -86.4% | -58.8% | -94.3% | ||
| Latest Twelve Months | 53.4% | 12.7% | -77.6% | -147.4% | -197.9% | -1.8% | ||
| Next Fiscal Year | 53.8% | 11.1% | 1612.9% | -283.5% | 307.2% | 189.9% | ||
| Two Fiscal Years Forward | 6.6% | 6.0% | -155.9% | 230.0% | 86.7% | 96.4% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 3.4x | 2.8x | NA | 17.2x | NA | NA | ||
| Price / LTM EPS | 4.7x | 12.9x | -15.9x | -7.3x | -5.7x | -134.7x | ||
| Price / Book | 2.0x | 1.5x | 20.2x | 10.7x | 8.0x | 2.1x | ||
| Price / Fwd Book | 2.2x | 1.5x | -10.0x | -52.5x | -6.7x | 0.1x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 1.5x | 8.0x | 20.2x | |||||
| Historical P/B Ratio | 0.8x | 3.3x | 64.2x | |||||
| Selected P/B Multiple | 2.8x | 2.9x | 3.1x | |||||
| (x) Book Value | 19 | 19 | 19 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | ZEAL | BAVA | INIT | BIOPOR | CURAS | STRAP | |
| Value of Common Equity | 31,271 | 18,351 | 167 | 615 | 243 | 40 | |
| (/) Shares Outstanding | 70.4 | 77.9 | 68.5 | 454.7 | 45.9 | 0.0 | |
| Implied Stock Price | 444.30 | 235.70 | 2.44 | 1.35 | 5.30 | 962.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 0.68 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 444.30 | 235.70 | 3.60 | 1.35 | 5.30 | 962.00 | |
| Trading Currency | DKK | DKK | SEK | DKK | DKK | DKK | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 0.68 | 1.00 | 1.00 | 1.00 | |